Letermovir, an antiviral drug for cytomegalovirus (CMV), was associated with reduced inflammation, improved CD4/CD8 T-cell ratios and better physical function for people with HIV on effective ...

The alafenamide formulation is much more rapidly absorbed by cells, meaning fewer kidney and bone-related side effects and, in theory at least, more ‘forgiveness’ of partial adherence. As has already ...

Two broadly neutralising antibodies, teropavimab and zinlirvimab, might be good partners for lenacapavir (Sunlenca) in a long-acting HIV treatment regimen, according to study results presented ...

Two more people appear to be free of HIV after stem cell transplants for cancer treatment, according to a pair of posters presented at the Conference on Retroviruses and Opportunistic Infections (CROI ...

A mutation that can undermine two-drug treatment with dolutegravir and lamivudine persists for at least 12 years in the ‘archive’ of HIV locked up in the DNA of blood cells in one in three people, ...

📢 With heavy hearts, we announce the proposed closure of our beloved charity, NAM aidsmap, this month. After 37 years of pioneering health journalism, community engagement, and empowerment through ...

It’s rare in any branch of medicine that a trial of a new drug can report 100% efficacy, and a first in HIV science. But that’s what happened on Friday, when Gilead Sciences announced that no HIV ...

In the same session, Dr Jenell Stewart of the Hennepin Healthcare Research Institute in Minneapolis, US argued that event-driven PrEP is demonstrably as effective as daily PrEP for gay men and trans ...

A positive diagnosis continues to be a source of isolation and stigma for people living with HIV, especially among trans people, younger people and women. Findings from the UK’s largest survey of ...

“State health department websites serve as a free and trusted resource for health professionals and community members to access health information,” write researchers from George Washington University ...

BHIVA recommends that people aged 40 and over should be offered a statin irrespective of lipid levels or estimated cardiovascular risk. People with HIV aged 40 and over with an estimated 10-year risk ...

By 2022, half of all patients eligible for this analysis were taking reduced-drug treatment. In people taking three-drug daily treatment in 2015, there was no change in the proportion who were virally ...